Dr. Barry Bloom – Dean of the Faculty and Joan L. and Julius H. Jacobson Professor of Public Health at Harvard School of Public Health. Dr. Bloom is a leader in international health and a former consultant to the White House who continues to pursue an active interest in bench science as the principal investigator of a laboratory researching the immune response to TB.
Dr. Queta Bond – Past President of the Burroughs-Wellcome Fund. Dr. Bond has served on the Board of Health Sciences Policy at the Institute of Medicine (IOM), as the Vice Chair of the Board of Scientific Counselors for the National Center for Infectious Diseases at the Centers for Disease Control and Pervention (CDC) and the chair of the Board of Regents of the National Library of Medicine.
Dr. Bruce Carter – President and Chief Executive Officer, ZymoGenetics and a board member of the Global Alliance for TB Drug Development (TB Alliance). Dr. Carter has led Zymogenetics, a Seattle-based biotech, since 1998 and has transformed Zymogenetics from an early research enterprise to a solid product development company. Dr. Gail Cassell, Ph.D. – Vice President, Lilly Scientific Affairs and Distinguished Research Scholar for Infectious Diseases. Dr. Cassell has been deeply involved in formulating science policy and legislation related to biomedical research and public health. She is a member of the IOM and serves on the IOM governing board. She recently served a three-year term on the Advisory Board of the Director of the CDC and as a member of the Secretary of Health and Human Services Advisory Council of Public Health Preparedness.
Bio Link: Dr. Gail Cassell, Ph.D.
Dr. Paul Farmer – Founder and Executive Director of Partners in Health, Presley Professor of Medical Anthropology at Harvard Medical School, and Associate Chief at the Division of Social Medicine and Health Inequalities at Brigham and Women’s Hospital. Dr. Farmer’s work draws primarily on active clinical practice and focuses on diseases that disproportionately afflict the poor. Dr. Farmer has pioneered novel, community-based treatment strategies for AIDS and TB (including multidrug-resistant tuberculosis).
Dr. Carole Heilman, Ph.D. – Director of the Division of Microbiology and Infectious Diseases (DMID) at the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). Dr. Heilman manages the scientific direction, oversight, and management of all extramural research programs on infectious diseases within the NIH.
Bio Link: Dr. Carole Heilman, Ph.D.
Dr. Barbara Laughon, Ph.D. – Senior Scientist for TB Drug Development Partnerships in the Office of the Director, DMID, NIAID, NIH. She is the primary NIH liaison with The Lilly TB Drug Discovery Initiative. She also serves as Chair of the Scientific Advisory Committee of the TB Alliance and was one of the original founding stakeholders of this public-private partnership. She is an active participant in the STOP-TB Partnership serving in working groups on New Drugs and TB/HIV co-infection. Dr. Laughon wills serve as Executive Secretary of the Board of Advisors.
Bio Link: Dr. Barbara Laughon, Ph.D.
Dr. Regina Rabinovitch – Director of Infectious Diseases for the Bill and Melinda Gates Foundation. Dr. Rabinovitch oversees the development and implementation of strategies for the prevention, treatment, and control of diseases of particular relevance to global health, including HIV/AIDS, TB, malaria, pneumonia, diarrhea, and neglected diseases.
Dr. Steve Reed, Ph.D. – Founder and Scientific Director of the Infectious Disease Research Institute (IDRI). Dr. Reed was also co-founder and Chief Scientific Officer of Corixa Corporation and founder of Dharma Therapeutics, a Seattle biotech developing transdermal delivery systems. Dr. Reed will serve as chair of the Board of Adivsors.
Bio Link: Dr. Steve Reed, Ph.D.
Dr. George Whitesides – Woodford L. and Ann A. Flowers University Professor at Harvard University. Dr. Whiteside has held advisory positions at the National Research Council, National Science Foundation and the Department of Defense. His present research interests include physical and organic chemistry, materials science, biophysics, complexity, surface science, microfluidics, self-assembly, micro- and nanotechnology, science for developing economies, origin of life, and cell-surface biochemistry.
Dr. Rachel Behrman, M.D. – Deputy Director of the Office of Medical Policy within the Center for Drug Evaluation and Research at the Food and Drug Administration (FDA). She also is Director of the Cross-Centers Initiatives Task Force in the Office of the Commissioner. She is an internist with a subspecialty in infectious diseases.Bio Link: Dr. Rachel Behrman, M.D.
Dr. Patrick Brennan – Distinguished Professor, Mycobacteria Research Laboratories in the Department of Microbiology, Immunology, and Pathology at Colorado State University. In the past 30 years, he has conducted leprosy research and is largely responsible for the progress in the basic research in leprosy today.
Bio Link: Dr. Patrick Brennan
Dr. Gail Cassell, Ph.D. – Vice President, Lilly Scientific Affairs and Distinguished Research Scholar for Infectious Diseases. Dr. Cassell has been deeply involved in formulating science policy and legislation related to biomedical research and public health. She is a member of the Institute of Medicine (IOM) and serves on the IOM governing board. She recently served a three-year term on the Advisory Board of the Director of the Centers for Disease Control and Prevention and as a member of the Secretary of Health and Human Services Advisory Council of Public Health Preparedness. Dr. Cassell will serve as Chair of the Scientific Steering Committee.
Bio Link: Dr. Gail Cassell, Ph.D.
Professor Richard Chaisson, M.D. – Professor of Medicine, Epidemiology and International Health at the Johns Hopkins University. He is currently Director of the Johns Hopkins Center for Tuberculosis Research, a multidisciplinary center with more than $60 million in grants for the study of TB from bench to bedside and director of the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE), an international research consortium funded by the Bill and Melinda Gates Foundation to assess the impact of novel strategies for controlling HIV-related TB.
Bio Link: Professor Richard Chaisson, M.D.
Dr. Stewart Cole – Professor of Microbial Pathogenesis at Ecole Polytechnique Federale de Lausanne, School of Life Sciences. He also is Director of the Global Health Institute, a center that will use cutting-edge techniques to seek solutions to treat and prevent TB. Dr. Cole's work on TB, leprosy, AIDS, gas gangrene and bacterial molecular genetics is widely acclaimed throughout the world. He was a leading member of the team of scientists who determined the complete nucleotide sequence for the AIDS virus. He also is considered to be a pioneer in the genomics of TB and leprosy bacilli.
Dr. Andrew Dahlem, Ph.D. – Vice President and Chief Operations Officer of Lilly Research Laboratories. He also is a member of the International Society for the Study of Xenobiotics, the Society of Toxicology, and the American Association for the Advancement of Science.
Bio Link: Dr. Andrew Dahlem, Ph.D.
Professor Jacques Grosset, M.D. – Professor, Center for Tuberculosis Research at Johns Hopkins University. In the past 45 years he has participated in the development of nearly all new drug regimens used for TB and a number of other mycobacterial diseases, namely leprosy, M. avium complex infection in HIV-infected persons, and M. ulcerans infection (Buruli ulcer).
Bio Link: Professor Jacques Grosset, M.D.
Dr. Edward Kesicki, Ph.D. - Director Small-Molecular Drug Discovery at IDRI. He has over 11 years experience in small-molecule drug discovery in the biotech industry. Dr. Kesicki is co-founder of the not-for-profit Afya World Medicines, which merged with IDRI in 2008. Prior to Afya, he was a senior staff scientist and group leader at ICOS Corporation.
Bio Link: Dr. Edward Kesicki, Ph.D.
Dr. Barbara Laughon, Ph.D. – Senior Scientist for TB Drug Development Partnerships in the Office of the Director, Division of Microbiology and Infectious Diseases (DMID) at the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). She is the primary NIH liaison with The Lilly TB Drug Discovery Initiative. She also serves as Chair of the Scientific Advisory Committee of the TB Alliance and was one of the original founding stakeholders of this public-private partnership. She is an active participant in the STOP-TB Partnership serving in working groups on New Drugs and TB/HIV co-infection.
Bio Link: Dr. Barbara Laughon, Ph.D.
Dr. Zhenkun Ma, Ph.D. – Head of Research at the TB Alliance. He guides the selection of new potential TB drug candidates and oversees preclinical development programs. He is an expert in the discovery aspects of antibacterial medicinal chemistry and in managing development programs of preclinical antibacterial candidates.
Bio Link: Dr. Zhenkun Ma, Ph.D.
Professor Carl Nathan, M.D. – Professor and Chair of Department Microbiology and Immunology at Weill Medical College at Cornell University. He is a Fellow at the American Academy of Microbiology and Ellison Medical Foundation Senior Scholar in Global Infectious Diseases.
Bio Link: Professor Carl Nathan, M.D.
Dr. Alan Palkowitz, Ph.D. – Vice President of Discovery Chemistry Research and Technologies at Lilly. He is responsible for Lilly Global Discovery Chemistry, which is accountable for the discovery of drug candidates targeting oncology, neuroscience, cardiovascular and metabolic diseases.
Bio Link: Dr. Alan Palkowitz, Ph.D.
Professor Tanya Parish, Ph.D. - Senior Scientist/Principal Investigator and Acting Director of the TB Drug Discovery Group at IDRI. She is a molecular microbiologist with 15 years experience with Mycobacterium tuberculosis. Tanya also holds a post as Professor of Mycobacteriology at the London Queen Mary's School of Medicine and Dentistry (UK), where she maintains an active research group investigating the biology and pathogenesis of Mycobacterium tuberculosis.
Bio Link: Professor Tanya Parish, Ph.D.
Dr. Christine Sizemore, Ph.D. – Chief of the Tuberculosis and other Mycobacterial Diseases Section at DMID, NIAID, NIH. She is a biologist trained in microbiology, infectious diseases and antimicrobial discovery.
Bio Link: Dr. Christine Sizemore, Ph.D.
Dr. Ken Tanaka, Ph.D. – Vice President of Research and Development at Paratek Pharmaceuticals. He has over 20 years of experience in research and development in the pharmaceutical industry at both large and small pharmaceutical companies.
Bio Link: Dr. Ken Tanaka, Ph.D.
Dr. Paul Wender – Bergstrom Professor of Chemistry at Stanford University. He is cofounder of the Quantitative Chemical Biology Program, sits on the science advisory boards of the Stanford Molecular Imaging Program and of the Stanford Epithelial Biology Program and an associate of the Program for Molecular and Genetic Medicine. He is a board member of iDDi, a not-for-profit international drug discovery institute focused on unmet medical needs in developing countries.
Professor Wong, Ph.D.
Bio Link: Professor Wong, Ph.D.
